Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 19;22(6):3130.
doi: 10.3390/ijms22063130.

Stem Cells-Derived Extracellular Vesicles: Potential Therapeutics for Wound Healing in Chronic Inflammatory Skin Diseases

Affiliations
Review

Stem Cells-Derived Extracellular Vesicles: Potential Therapeutics for Wound Healing in Chronic Inflammatory Skin Diseases

Enzo Manchon et al. Int J Mol Sci. .

Abstract

Endosome-derived small extracellular vesicles (EVs), often referred to as exosomes, are produced by almost all, if not all, cell types, and are critical for intercellular communication. They are composed of a lipid bilayer associated with membrane proteins and contain a payload of lipids, proteins and regulatory RNAs that depends on the parental cell physiological condition. By transferring their "cargo", exosomes can modulate the phenotype of neighboring and distant cells. Stem cells (SC) were widely studied for therapeutic applications regarding their regenerative/reparative potential as well as their immunomodulatory properties. Whether from autologous or allogeneic source, SC beneficial effects in terms of repair and regeneration are largely attributed to their paracrine signaling notably through secreted EVs. Subsequently, SC-derived EVs have been investigated for the treatment of various diseases, including inflammatory skin disorders, and are today fast-track cell-free tools for regenerative/reparative strategies. Yet, their clinical application is still facing considerable challenges, including production and isolation procedures, and optimal cell source. Within the emerging concept of "allogeneic-driven benefit" for SC-based therapies, the use of EVs from allogeneic sources becomes the pragmatic choice although a universal allogeneic cell source is still needed. As a unique temporary organ that ensures the mutual coexistence of two allogeneic organisms, mother and fetus, the human placenta offers a persuasive allogeneic stem cell source for development of therapeutic EVs. Advancing cell-free therapeutics nurtures great hope and provides new perspectives for the development of safe and effective treatment in regenerative/reparative medicine and beyond. We will outline the current state of the art in regard of EVs, summarize their therapeutic potential in the context of skin inflammatory disorders, and discuss their translational advantages and hurdles.

Keywords: chronic inflammation; exosomes; extracellular vesicles; regenerative medicine; skin; stem cells; wound healing.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of exosomes endosomal budding detailing their different components and mode of action on recipient cells.
Figure 2
Figure 2
Timeline of physiological skin wound healing phases.
Figure 3
Figure 3
Potential effects of stem cell (SC)-derived EVs/Exs on skin wound healing.
Figure 4
Figure 4
Schematic representation of engineering approaches towards clinical applications.

Similar articles

Cited by

References

    1. Wood K.J., Issa F., Hester J. Understanding Stem Cell Immunogenicity in Therapeutic Applications. Trends Immunol. 2016;37:5–16. doi: 10.1016/j.it.2015.11.005. - DOI - PubMed
    1. Charron D., Suberbielle-Boissel C., Tamouza R., Al-Daccak R. Anti-HLA antibodies in regenerative medicine stem cell therapy. Hum. Immunol. 2012;73:1287–1294. doi: 10.1016/j.humimm.2012.06.010. - DOI - PubMed
    1. Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell. 2020;27:523–531. doi: 10.1016/j.stem.2020.09.014. - DOI - PubMed
    1. Lauden L., Boukouaci W., Borlado L.R., Lopez I.P., Sepulveda P., Tamouza R., Charron D., Al-Daccak R. Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. Circ. Res. 2013;112:451–464. doi: 10.1161/CIRCRESAHA.112.276501. - DOI - PubMed
    1. Boukouaci W., Lauden L., Siewiera J., Dam N., Hocine H.R., Khaznadar Z., Tamouza R., Borlado L.R., Charron D., Jabrane-Ferrat N., et al. Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence. Cardiovasc Res. 2014;104:290–302. doi: 10.1093/cvr/cvu208. - DOI - PubMed